Idiopathic Multicentric Castleman Disease-TAFRO: A Potentially Curable Disease?

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Idiopathic multicentric Castleman disease (iMCD)-TAFRO is a severe subtype of iMCD, characterized by a cytokine storm and often requiring indefinite treatment.
• Current understanding suggests iMCD-TAFRO is incurable, necessitating continuous therapy, though long-term data on treatment cessation are limited.

Purpose of the Study:

• To evaluate the feasibility and outcomes of treatment discontinuation in patients with iMCD-TAFRO who achieved biochemical complete response (CR).
• To identify factors associated with sustained remission and disease progression after stopping therapy in iMCD-TAFRO.

Main Methods:

• A retrospective analysis of 27 iMCD-TAFRO patients who discontinued treatment after achieving biochemical CR.
• Data collected included treatment history, time to progression, and follow-up duration (median 31 months).

Main Results:

• 85.2% of patients maintained biochemical CR after treatment discontinuation, with only 14.8% experiencing disease progression (PD).
• Patients who progressed had significantly lower pretreatment CRP levels compared to those maintaining remission (p=0.018).
• Progression-free survival (PFS) at 3 years was 85.2%, and all patients remained alive.

Conclusions:

• Treatment discontinuation may be a viable option for a subset of iMCD-TAFRO patients who achieve biochemical CR.
• Lower pretreatment CRP may predict a higher risk of progression upon treatment cessation.
• Further investigation into personalized treatment strategies, including discontinuation, is warranted for iMCD-TAFRO management.